Circadian rhythm heterogeneity modulates drug response variations in neuroblastoma models
Cell Reports · 2026-02 · 45 (2) · 116975
DOI: 10.1016/j.celrep.2026.116975 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cell Reports, 2026-02. Verfasst von Carolin Ector und 9 weiteren Autor:innen. Beteiligte Einrichtung: Charité Comprehensive Cancer Center, Charité - Universitätsmedizin Berlin, 10117 Berlin, Germany; Institute for Theoretical Biology, Humboldt-Univers…. Hauptthemen laut MEDLINE: Neuroblastoma, Circadian Rhythm, Antineoplastic Agents, Models, Biological. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Deutsche Forschungsgemeinschaft, Federal Ministry of Education and Research Bonn Office, National Research Fund.
Abstract (Originalsprache)
Circadian clocks regulate essential cellular functions and influence cancer development and treatment outcomes. Aligning therapy with circadian rhythms can improve efficacy and reduce toxicity, yet whether neuroblastoma, a heterogeneous pediatric tumor, maintains circadian function remains unclear. Here, we systematically profiled circadian dynamics across 12 neuroblastoma cell models using long-term bioluminescence assays and computational analysis. Our findings reveal heterogeneous circadian patterns ranging from robust to arrhythmic, which we linked to distinct neuroblastoma genetic features. By integrating drug sensitivity data, we identified candidate compounds whose effectiveness correlates with circadian expression profiles. Moreover, time-of-day treatment assays with the ALK inhibitor lorlatinib and frontline chemotherapeutics revealed distinct temporal drug responses that were more pronounced in circadian-competent than weakly rhythmic cell lines. Together, these findings establish circadian heterogeneity as a previously unrecognized dimension of neuroblastoma biology and highlight the therapeutic potential of chronotherapy approaches for improved treatment efficacy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Charité Comprehensive Cancer Center, Charité - Universitätsmedizin Berlin, 10117 Berlin, Germany; Institute for Theoretical Biology, Humboldt-Universität zu Berlin, 10115 Berlin, Germany.
- Institute for Theoretical Biology, Humboldt-Universität zu Berlin, 10115 Berlin, Germany.
- Department of Life Sciences and Medicine, University of Luxembourg, 4365 Esch-sur-Alzette, Luxembourg.
- Department of Pediatric Oncology, Hematology and Stem Cell Transplantation, Charité - Universitätsmedizin Berlin, Charitéplatz 1, 10117 Berlin, Germany.
- Charité Comprehensive Cancer Center, Charité - Universitätsmedizin Berlin, 10117 Berlin, Germany; German Cancer Consortium (DKTK), Berlin, Germany.
- Laboratory of Chronobiology, Charité - Universitätsmedizin Berlin, 10117 Berlin, Germany.
Förderung
- Deutsche Forschungsgemeinschaft
- Federal Ministry of Education and Research Bonn Office
- National Research Fund
Zitieren
APA
Ector, C., Schmal, C., Didier, J., De Landtsheer, S., Schulte, J. H., Keilholz, U., Sauter, T., Kramer, A., Herzel, H., & Granada, A. E. (2026). Circadian rhythm heterogeneity modulates drug response variations in neuroblastoma models. Cell Reports, 45(2), 116975. https://doi.org/10.1016/j.celrep.2026.116975
Vancouver
Ector C, Schmal C, Didier J, De Landtsheer S, Schulte JH, Keilholz U, et al. Circadian rhythm heterogeneity modulates drug response variations in neuroblastoma models. Cell Reports. 2026;45(2):116975. doi:10.1016/j.celrep.2026.116975
BibTeX
@article{Ector2026,
author = {Ector, Carolin and Schmal, Christoph and Didier, Jeff and De Landtsheer, Sébastien and Schulte, Johannes H and Keilholz, Ulrich and Sauter, Thomas and Kramer, Achim and Herzel, Hanspeter and Granada, Adrián E},
title = {Circadian rhythm heterogeneity modulates drug response variations in neuroblastoma models},
journal = {Cell Reports},
year = {2026},
volume = {45},
number = {2},
pages = {116975},
doi = {10.1016/j.celrep.2026.116975}
}
EUVIMED